VanEck Vectors Morningstar Durable Dividend ETF DURA 深 滬
等待開盤 03-26 09:30:00 美东时间
37.2715
+0.210
+0.57%
華盛通- 最 高37.2715
- 今 開37.33
- 成交量 244股
- 最 低 37.2715
- 昨 收 37.0619
- 總市值 4472.58万
- 52周最高 38.4289
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 28.1734
- 委 比 8.05%
- 總股本 120.00万
- 歷史最高 38.4289
- 量 比 0.20
- 振 幅 0.00%
- 歷史最低 13.6173
- 每 手 1
- 風險率 2.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Gulftex Energy Closes $1.0 Billion Recapitalization, Led By Endurance Investment Partners
BRIEF-Gulftex Energy Closes $1.0 Billion Recapitalization, Led By Endurance Investment Partners GULFTEX ENERGY CLOSES $1.0 BILLION RECAPITALIZATION, LED BY ENDURANCE INVESTMENT PARTNERS Source text: ID:nBw8qzCdGa Further company coverage: [ ]
03-24 21:03
EyePoint sues Ocular over claims related to lead asset
EyePoint (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) in a Massachusetts federal court, alleging that its rival eye drug developer made false claims regarding its lead candidate, Durav...
03-21 22:23
BRIEF-Duravent Group Secured Significant Strategic Growth Investment From Bain Capital Financial Terms Not Disclosed
BRIEF-Duravent Group Secured Significant Strategic Growth Investment From Bain Capital Financial Terms Not Disclosed March 18 (Reuters) - DURAVENT GROUP: SECURED SIGNIFICANT STRATEGIC GROWTH INVESTMENT FROM BAIN CAPITAL; FINANCIAL TERMS NOT DISCLOSED Source text: ID:nBw3b77Kfa Further company covera
03-18 20:06
BRIEF-EASA Extends Duration Of Conflict Zone Information Bulletin For Middle East And Persian Gulf Until March 18
BRIEF-EASA Extends Duration Of Conflict Zone Information Bulletin For Middle East And Persian Gulf Until March 18 March 11 (Reuters) - EASA: EXTENDS DURATION OF CONFLICT ZONE INFORMATION BULLETIN FOR MIDDLE EAST AND PERSIAN GULF UNTIL MARCH 18 Source text (Gdansk Newsroom) (( Gdansk.newsroom@thomson
03-11 18:40
EyePoint Pharmaceuticals Q4 revenue plunges, net loss widens
EyePoint Pharmaceuticals Q4 revenue plunges, net loss widens Overview Biopharmaceutical firm's Q4 revenue fell sharply yr/yr Net loss for Q4 widened due to increased operating expenses Company has over $300 mln cash and investments, funding operations into Q4 2027 Outlook EyePoint expects topline da
03-04 20:09
EyePoint Q4 net revenue USD 0.6 million -94.7%
EyePoint Q4 net revenue USD 0.6 million -94.7% EyePoint reported Q4 FY2025 total net revenue of USD 0.6 million (down 94.6%), including net product revenue of USD 0.3 million (down 61.4%) and license and royalty revenue of USD 0.3 million (down 97.2%), with the decline in license and royalties prima
03-04 20:03
RadNet Q4 revenue rises, adjusted EPS beats estimates
RadNet Q4 revenue rises, adjusted EPS beats estimates Overview Diagnostic imaging provider's Q4 revenue rose 14.8% yr/yr to $547.7 mln Adjusted EPS for Q4 beat analyst expectations Company anticipates 2026 revenue growth of 17%-19% in Imaging Center segment Outlook RadNet anticipates 2026 Imaging Ce
03-02 19:08
BRIEF-RBC Analyst Helima Croft On US-Iran Strikes Says Oil Price Impact Of Today’s Military Action Will Hinge On Whether IRGC Folds In Face Of Aerial Onslaught
BRIEF-RBC Analyst Helima Croft On US-Iran Strikes Says Oil Price Impact Of Today’s Military Action Will Hinge On Whether IRGC Folds In Face Of Aerial Onslaught Feb 28 (Reuters) - RBC ANALYST HELIMA CROFT ON US-IRAN STRIKES: OIL PRICE IMPACT OF TODAY’S MILITARY ACTION WILL HINGE ON WHETHER IRGC FOLDS
03-01 11:11
BRIEF-Endurance Gold Announces $8 Mln Life Private Placement Of Flow-Through Units & Units
BRIEF-Endurance Gold Announces $8 Mln Life Private Placement Of Flow-Through Units & Units Feb 19 (Reuters) - Endurance Gold Corp EDG.V : ENDURANCE GOLD ANNOUNCES $8 MILLION LIFE PRIVATE PLACEMENT OF FLOW-THROUGH UNITS AND UNITS ENDURANCE GOLD CORP: NET PROCEEDS FROM SALE OF HD UNITS WILL BE USED FO
02-20 06:59
BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCC
BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCC Feb 19 (Reuters) - Bicara Therapeutics Inc BCAX.O : FICERAFUSP ALFA 2000MG Q2W DEMONSTRATES DEEP, DURABLE RESPONSES IN 1L R/M HPV-NEGATIVE HNSCC AND SUPPORTS DEVELOPMENT OF LESS FREQUENT DOSING REGIMEN
02-20 06:46
